Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ghrelin treatment after cardiac arrest coma
NL-OMON46402Phase 2Active, not recruiting
- Sponsor
- University of Twente
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypoxic-ischemic encephalopathy (HIE), anoxic encephalopathy and coma comparing Acyl-ghrelin with Placebo (2 arms). Primary endpoints: Functional outcome at 6 months and Safety. Started Jan 2019; status: active, not recruiting.
02
Drugs
acyl-ghrelin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)anoxic encephalopathycoma
Beyond the preview
Go deeper on NL-OMON46402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46402.